Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Mickael Hiligsmann; Annelies Boonen; Carmen D. Dirksen; Wafa Ben Sedrine; Jean-Yves Reginster

doi:10.1586/ERP.12.76

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Mickael Hiligsmann^*, Annelies Boonen, Carmen D. Dirksen, Wafa Ben Sedrine, Jean-Yves Reginster

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures.

Original language	English
Pages (from-to)	19-28
Journal	Expert Review of Pharmacoeconomics & Outcomes Research
Volume	13
Issue number	1
DOIs	https://doi.org/10.1586/ERP.12.76
Publication status	Published - Feb 2013

Keywords

cost-effectiveness
denosumab
osteoporosis

Access to Document

10.1586/ERP.12.76

Cite this

@article{f22331eacba543c18ec7395475909acf,

title = "Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women",

abstract = "Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures.",

keywords = "cost-effectiveness, denosumab, osteoporosis",

author = "Mickael Hiligsmann and Annelies Boonen and Dirksen, {Carmen D.} and {Ben Sedrine}, Wafa and Jean-Yves Reginster",

year = "2013",

month = feb,

doi = "10.1586/ERP.12.76",

language = "English",

volume = "13",

pages = "19--28",

journal = "Expert Review of Pharmacoeconomics & Outcomes Research",

issn = "1473-7167",

publisher = "Routledge/Taylor & Francis Group",

number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

AU - Hiligsmann, Mickael

AU - Boonen, Annelies

AU - Dirksen, Carmen D.

AU - Ben Sedrine, Wafa

AU - Reginster, Jean-Yves

PY - 2013/2

Y1 - 2013/2

N2 - Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures.

AB - Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures.

KW - cost-effectiveness

KW - denosumab

KW - osteoporosis

U2 - 10.1586/ERP.12.76

DO - 10.1586/ERP.12.76

M3 - Article

SN - 1473-7167

VL - 13

SP - 19

EP - 28

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

IS - 1

ER -